NO20053994L - Fettsyrer med middels kjedelengde, glycerider og analoger som stimulatorer av erytropoese - Google Patents

Fettsyrer med middels kjedelengde, glycerider og analoger som stimulatorer av erytropoese

Info

Publication number
NO20053994L
NO20053994L NO20053994A NO20053994A NO20053994L NO 20053994 L NO20053994 L NO 20053994L NO 20053994 A NO20053994 A NO 20053994A NO 20053994 A NO20053994 A NO 20053994A NO 20053994 L NO20053994 L NO 20053994L
Authority
NO
Norway
Prior art keywords
erythropoiesis
stimulators
glycerides
analogues
fatty acids
Prior art date
Application number
NO20053994A
Other languages
English (en)
Other versions
NO334085B1 (no
NO20053994D0 (no
Inventor
Lyne Gagnon
Pierre Laurin
Christopher Penney
Boulous Zacharie
Original Assignee
Prometic Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biosciences Inc filed Critical Prometic Biosciences Inc
Publication of NO20053994D0 publication Critical patent/NO20053994D0/no
Publication of NO20053994L publication Critical patent/NO20053994L/no
Publication of NO334085B1 publication Critical patent/NO334085B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Anvendelse av en sammensetning omfattende en forbindelse ifølge hvilke som helst av formlene I, II, IIa, III og IIIa; eller kombinasjon derav hvori hver R1 uavhengig er C7-11-alkyl; A og B uavhengig er H eller CO-R1; R2 er H eller C1-4-alkyl; M er et metall monokation ( k= 1) eller dikation (k = 2); Y er O eller NH; og Z er O, NH, CH2O eller en binding; for fremstilling av et medikament for stimulering av erytropoese. Foretrukket omfatter sammensetningen ytterligere human erytropoietin.
NO20053994A 2003-02-07 2005-08-26 Anvendelse av fettsyrer med middels kjedelengde, glyserider og analoger for fremstilling av et medikament for stimulering av erytropoese NO334085B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44545403P 2003-02-07 2003-02-07
PCT/GB2004/000457 WO2004069237A1 (en) 2003-02-07 2004-02-06 Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis

Publications (3)

Publication Number Publication Date
NO20053994D0 NO20053994D0 (no) 2005-08-26
NO20053994L true NO20053994L (no) 2005-10-06
NO334085B1 NO334085B1 (no) 2013-12-09

Family

ID=32850990

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053994A NO334085B1 (no) 2003-02-07 2005-08-26 Anvendelse av fettsyrer med middels kjedelengde, glyserider og analoger for fremstilling av et medikament for stimulering av erytropoese

Country Status (28)

Country Link
US (1) US9682054B2 (no)
EP (1) EP1592416B1 (no)
JP (1) JP5390070B2 (no)
KR (1) KR101120775B1 (no)
CN (1) CN100427081C (no)
AP (1) AP2005003367A0 (no)
AR (1) AR043120A1 (no)
AT (1) ATE419846T1 (no)
AU (1) AU2004210193B2 (no)
BR (1) BRPI0407276A (no)
CA (1) CA2515160C (no)
CY (1) CY1108963T1 (no)
DE (2) DE04708802T1 (no)
DK (1) DK1592416T3 (no)
EA (1) EA009939B1 (no)
ES (1) ES2255467T3 (no)
IL (1) IL170057A (no)
JO (1) JO2705B1 (no)
MA (1) MA27664A1 (no)
MX (1) MXPA05008382A (no)
MY (1) MY140913A (no)
NO (1) NO334085B1 (no)
NZ (1) NZ541593A (no)
PT (1) PT1592416E (no)
SI (1) SI1592416T1 (no)
TN (1) TNSN05189A1 (no)
WO (1) WO2004069237A1 (no)
ZA (1) ZA200506246B (no)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745488B2 (en) 2001-04-18 2010-06-29 Prometic Biosciences, Inc. Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
US20050232981A1 (en) * 2004-04-15 2005-10-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
DK2332977T3 (en) 2004-07-23 2016-02-29 Acceleron Pharma Inc ActRII receptor polypeptides
AP2007003939A0 (en) * 2004-09-03 2007-04-30 Prometic Biosciences Inc Substituted purinyl derivatives with immunomodulator and chemoprotective activity and use alone or with medium-chain length fatty acids or glycerides
US8071580B2 (en) * 2004-10-01 2011-12-06 Prometic Biosciences Inc. Medium-chain length fatty alcohols as stimulators of hematopoiesis
WO2006086871A1 (en) 2004-10-01 2006-08-24 Prometic Biosciences Inc. Medium-chain length fatty alcohols as stimulators of hematopoiesis
CA2631013C (en) 2005-11-23 2019-06-11 Acceleron Pharma Inc. Activin-actriia antagonists and uses for promoting bone growth
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
ES2415666T3 (es) 2007-02-01 2013-07-26 Acceleron Pharma, Inc. Composiciones farmacéuticas que comprenden antagonistas de Activina-ActRIIa para uso en la prevención o el tratamiento de metástasis de cáncer de mama o pérdida ósea relacionada con el cáncer de mama
TW201627320A (zh) 2007-02-02 2016-08-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
CN101687016B (zh) 2007-02-09 2014-12-31 阿塞勒隆制药公司 活化素-actriia拮抗剂和促进癌症患者骨骼生长的用途
US7960343B2 (en) 2007-09-18 2011-06-14 Acceleron Pharma Inc. Activin-ActRIIa antagonists and uses for decreasing or inhibiting FSH secretion
JP5575655B2 (ja) 2007-11-02 2014-08-20 プロメティック・バイオサイエンシーズ・インコーポレイテッド 腎保護剤としての中鎖長脂肪酸およびグリセリド
TWI448290B (zh) * 2007-12-19 2014-08-11 Prometic Biosciences Inc 與健擇他濱（ｇｅｍｃｉｔａｂｉｎｅ）組合用於胰臟癌之治療的中等鏈長脂肪酸、鹽類及三酸甘油酯
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
DK3750552T5 (da) 2008-08-14 2024-08-26 Acceleron Pharma Inc Gdf-fælder
BRPI0918652B1 (pt) 2008-09-17 2021-10-19 Chiasma, Inc. Composição farmacêutica compreendendo um meio hidrofóbico e uma forma sólida que compreende polipeptídeo e sal de ácido graxo de cadeia média, processo de produção da mesma e forma de dosagem oral
WO2010144452A1 (en) 2009-06-08 2010-12-16 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
KR20180026795A (ko) 2009-06-12 2018-03-13 악셀레론 파마 인코포레이티드 절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질
EP3117829B1 (en) * 2009-08-13 2020-10-07 Acceleron Pharma Inc. Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
AU2010322011B2 (en) 2009-11-17 2016-03-31 Acceleron Pharma Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
CA2817008A1 (en) 2010-11-08 2012-05-18 Acceleron Pharma Inc. Actriia binding agents and uses thereof
TWI572352B (zh) * 2012-03-01 2017-03-01 波麥堤克藥學Ｓｍｔ有限公司 用於製備具中鏈長度之脂肪酸的三酸甘油酯之方法
RU2678117C2 (ru) 2012-11-02 2019-01-23 Селджин Корпорейшн Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
CN102973922B (zh) * 2012-12-18 2016-02-03 华东理工大学 一种融合蛋白的应用
MX2016016531A (es) 2014-06-13 2017-04-25 Acceleron Pharma Inc Metodos y composiciones para el tratamiento de las ulceras.
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
HUE062189T2 (hu) 2014-12-03 2023-09-28 Celgene Corp Aktivin-ACTRII-antagonisták és alkalmazások mielodiszpláziás szindróma kezelésére
US10238709B2 (en) 2015-02-03 2019-03-26 Chiasma, Inc. Method of treating diseases
US20170021029A1 (en) * 2015-04-15 2017-01-26 Jeffrey Charles Raber Topical formulations and uses
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871768A (en) 1984-07-12 1989-10-03 New England Deaconess Hospital Corporation Dietary supplement utilizing ω-3/medium chain trigylceride mixtures
US6060459A (en) 1987-10-28 2000-05-09 Pro-Neuron, Inc. Enhancing blood cell count with oxypurine nucleosides
US5011852A (en) 1988-07-25 1991-04-30 Applied Analytical Industries, Inc. Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
JP3014119B2 (ja) * 1990-05-28 2000-02-28 雪印乳業株式会社 直腸投与用赤血球造血剤
JP3249147B2 (ja) 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
EP0495187B1 (en) * 1991-01-15 1997-01-22 Hemosphere, Inc. Protein nanomatrixes and method of production
JPH05163160A (ja) 1991-12-13 1993-06-29 Snow Brand Milk Prod Co Ltd 免疫低下に伴う感染症の予防及び治療用栄養剤
US5214035A (en) 1992-04-16 1993-05-25 Hoechst-Roussel Agri-Vet Company Thixotropic formulations
US5318781A (en) * 1993-04-06 1994-06-07 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
US20010003739A1 (en) * 1993-06-24 2001-06-14 Astrazeneca Ab Systemic administration of a therapeutic preparation
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
AU7082694A (en) 1994-05-10 1995-11-29 Kitasato Institute, The Hematopoietic stem cell proliferation accelerator
US5470861A (en) 1994-08-04 1995-11-28 Hoffmann-La Roche Inc. Method of promoting hair growth
US5549905A (en) 1994-10-18 1996-08-27 Clintec Nutrition Co. Enternal composition for pediatric patients
IT1275802B1 (it) 1994-11-03 1997-10-17 Hoffmann La Roche Composizione di interferone
GB9516268D0 (en) 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
AUPN933396A0 (en) 1996-04-17 1996-05-09 Pfizer Pty Limited Non-aqueuos oral-drench compositions containing avermectin compounds
US5851534A (en) 1996-05-03 1998-12-22 Dynagen, Inc. Methods for prevention and/or treatment of neutropenia
JPH10265380A (ja) 1997-03-17 1998-10-06 Bristol Myers Squibb Co 抗ガン剤
WO1999011242A1 (en) * 1997-09-04 1999-03-11 Biozone Laboratories, Inc. Oral liposomal delivery system
NZ504188A (en) * 1997-11-14 2001-10-26 Skyepharma Inc Emulsification process for preparing multivesicular liposomes
BR9814693B1 (pt) 1997-11-19 2011-04-19 suspensões de polìmero fluidificado de polissacarìdeos catiÈnicos em emolientes e processo para preparação de uma composição para cuidado pessoal.
EP1061932B1 (en) * 1997-11-20 2006-01-25 Gil Ja Jhon Pharmaceutical composition containing extracts of cervus nippon antlers having growth-stimulating activities of hematopoietic stem cells and megakaryocytes
ATE271376T1 (de) * 1998-02-23 2004-08-15 Cilag Ag Int Liposomale erythropoietin-dispersion
CN1160079C (zh) 1998-03-11 2004-08-04 格勒兰制药株式会社 发泡性肠溶制剂
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
JP2003513019A (ja) 1999-09-27 2003-04-08 ソーナス ファーマシューティカルス，インコーポレイテッド トコール可溶性治療剤の組成物
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
WO2001095914A1 (en) 2000-06-14 2001-12-20 William Leslie Porter Lipids for modulating immune response
US6967028B2 (en) 2000-07-31 2005-11-22 Mainelab Prolonged release microspheres for injectable administration
IL142535A0 (en) 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
US7745488B2 (en) * 2001-04-18 2010-06-29 Prometic Biosciences, Inc. Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
US20040052836A1 (en) 2002-09-13 2004-03-18 Li Luk Chiu Pharmaceutical compositions containing at least one stable liposphere having an improved shelf life
US6725510B1 (en) 2003-04-25 2004-04-27 Almetta Clyburn Inclining coffin
AU2004261461B2 (en) 2003-07-25 2008-12-18 Prometic Pharma Smt Limited Preparation of metal salts of medium-chain fatty acids
AP2007003939A0 (en) 2004-09-03 2007-04-30 Prometic Biosciences Inc Substituted purinyl derivatives with immunomodulator and chemoprotective activity and use alone or with medium-chain length fatty acids or glycerides
US8071580B2 (en) 2004-10-01 2011-12-06 Prometic Biosciences Inc. Medium-chain length fatty alcohols as stimulators of hematopoiesis

Also Published As

Publication number Publication date
ZA200506246B (en) 2006-12-27
DE602004018902D1 (de) 2009-02-26
SI1592416T1 (sl) 2009-06-30
BRPI0407276A (pt) 2006-01-31
ATE419846T1 (de) 2009-01-15
NO334085B1 (no) 2013-12-09
PT1592416E (pt) 2009-04-03
CA2515160A1 (en) 2004-08-19
AP2005003367A0 (en) 2005-09-30
AU2004210193B2 (en) 2007-07-12
AR043120A1 (es) 2005-07-20
AU2004210193A1 (en) 2004-08-19
CY1108963T1 (el) 2014-07-02
JO2705B1 (ar) 2014-03-15
CN100427081C (zh) 2008-10-22
EA009939B1 (ru) 2008-04-28
EP1592416B1 (en) 2009-01-07
EP1592416A1 (en) 2005-11-09
EA200501267A1 (ru) 2006-02-24
ES2255467T1 (es) 2006-07-01
TNSN05189A1 (en) 2007-06-11
DK1592416T3 (da) 2009-04-20
NZ541593A (en) 2009-05-31
US9682054B2 (en) 2017-06-20
IL170057A (en) 2011-09-27
CA2515160C (en) 2013-01-08
ES2255467T3 (es) 2009-05-01
KR20050118671A (ko) 2005-12-19
MXPA05008382A (es) 2005-11-04
DE04708802T1 (de) 2006-06-22
MA27664A1 (fr) 2005-12-01
JP5390070B2 (ja) 2014-01-15
JP2006516987A (ja) 2006-07-13
KR101120775B1 (ko) 2012-04-18
WO2004069237A1 (en) 2004-08-19
US20060128800A1 (en) 2006-06-15
MY140913A (en) 2010-01-29
NO20053994D0 (no) 2005-08-26
CN1753665A (zh) 2006-03-29

Similar Documents

Publication Publication Date Title
NO20053994L (no) Fettsyrer med middels kjedelengde, glycerider og analoger som stimulatorer av erytropoese
AR004219A1 (es) Nuevos derivados de quinazolina, procedimientos para su preparacion, composiciones que los contienen y su uso en la preparacion de medicamentos,particularmente en el tratamiento de trastornos inflamatorios
IS2734B (is) Pýrasólafleiður og notkun þar á, ásamt lyfjasamsetningum
PE20020476A1 (es) Derivados de glucopiranosiloxibencilbenceno y composiciones farmaceuticas que comprenden los mismos
SV1999000118A (es) Nuevos derivados de pirazol substituidos ref. lea 33188-sv
MX9701893A (es) Nuevos inhibidores de la prostaglandinsintasa.
CY1112139T1 (el) Μια φαρμακευτικη συνθεση περιλαμβανουσα κρυσταλλικη ριτοναβιρη μορφη ιι και ενα παρασκευασμα εξ αυτης
ATE235476T1 (de) Thiazolidindione derivate, ihre herstellung und verwendung
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
ATE98634T1 (de) Acryloylsubstituierte pyrrol-derivate.
AR082075A1 (es) Derivados de dioxima eter microbicidas
AR029214A1 (es) Compuestos inhibidores de fosfodiesterasa - 4: 8 - arilquinolinas sustituidas, composiciones farmaceuticas, metodo de tratamiento que las utiliza
WO2004080922A3 (en) Substituted vitamin d analogues and their therapeutic uses
YU29300A (sh) Katalizovane reakcije prelaznog metala bazirane na hiralnim amin oksazolinil ligandima
SG145570A1 (en) 4-æ7-halo-2-quino(xa-)linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents
BG103426A (en) Derivatives of substituted 4-biphenyl-4-hydroxy-oil acids as inhibitors of matrix metalloproteases
DK471687D0 (da) Quinoxalinforbindelser, deres fremstilling og anvendelse
DK1525188T3 (da) Hidtil ukendte derivater af 4,4-dithiobis-(3-aminobutan-1-sulfonater) og sammensætninger, der indeholder dem
DK0421829T3 (da) Nye benzopyranon-beta-D-thioxylosider, fremgangsmåde til deres fremstilling og deres terapeutiske anvendelse
AR029468A1 (es) Derivados de aminoacidos n-mercaptoacilados, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR033651A1 (es) Derivados de pirimidina-2,4,6-triona, composiciones farmaceuticas que contienen dichos compuestos y el empleo de los mismos para la manufactura de un medicamento
ATE119890T1 (de) Aminoketonderivate und ihre verwendung.
ES2135351B1 (es) Derivados de 5-aroilnaftaleno.
AR031438A1 (es) Ciclohexil(alquil)-propanolaminas, su preparacion y composiciones farmaceuticas que las contienen
ATE88176T1 (de) 2-hydroxy-3-aryloxy-propylaminderivate mit kardiovaskulaerer wirkung.

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: PROMETIC PHARMA SMT LIMITED, GB

MM1K Lapsed by not paying the annual fees